NASDAQ:OCULOcular Therapeutix Stock Price, Forecast & News

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OCUL stock has increased by 27.9% and is now trading at $6.84. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ocular Therapeutix.

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Ocular Therapeutix.

Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings data on Friday, May, 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01. The biopharmaceutical company had revenue of $2.61 million for the quarter, compared to analysts' expectations of $2.66 million. Ocular Therapeutix had a negative return on equity of 6,659.51% and a negative net margin of 1,430.64%. View Ocular Therapeutix's earnings history.

Ocular Therapeutix issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.6-2.6 million, compared to the consensus revenue estimate of $3.09 million.

6 analysts have issued 12-month target prices for Ocular Therapeutix's stock. Their forecasts range from $5.00 to $11.00. On average, they expect Ocular Therapeutix's share price to reach $8.60 in the next year. This suggests a possible upside of 25.7% from the stock's current price. View analysts' price targets for Ocular Therapeutix.

News coverage about OCUL stock has trended positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ocular Therapeutix earned a news sentiment score of 2.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near future. View the latest news aboutOcular Therapeutix.

Some companies that are related to Ocular Therapeutix include BELLUS Health (BLUSF), Karyopharm Therapeutics (KPTI), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Akcea Therapeutics (AKCA), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), Passage Bio (ZNTL), Portola Pharmaceuticals (PTLA), INDIVIOR PLC/S (INVVY), Tricida (TCDA), Cytokinetics (CYTK), ZEALAND PHARMA/S (ZEAL), Supernus Pharmaceuticals (SUPN) and MacroGenics (MGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Celgene (CELG), Inovio Pharmaceuticals (INO), Omeros (OMER), Gilead Sciences (GILD), Cara Therapeutics (CARA), Exelixis (EXEL) and TG Therapeutics (TGTX).

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Ocular Therapeutix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.44%), Deltec Asset Management LLC (3.94%), Ikarian Capital LLC (2.92%), State Street Corp (1.54%), Geode Capital Management LLC (1.23%) and EAM Investors LLC (0.65%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends for Ocular Therapeutix.

OCUL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deltec Asset Management LLC, UBS Group AG, Levin Capital Strategies L.P., Quilter Plc, and Wells Fargo & Company MN. View insider buying and selling activity for Ocular Therapeutix.

OCUL stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, EAM Investors LLC, EAM Global Investors LLC, Invesco Ltd., State Street Corp, Geode Capital Management LLC, Raymond James & Associates, and Fred Alger Management LLC. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc, Richard L Md Lindstrom, and Summer Road Llc. View insider buying and selling activity for Ocular Therapeutix.

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OCUL stock can currently be purchased for approximately $6.84.

Ocular Therapeutix has a market capitalization of $364.98 million and generates $4.23 million in revenue each year. The biopharmaceutical company earns $-86,370,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Ocular Therapeutix employs 161 workers across the globe.

The official website for Ocular Therapeutix is www.ocutx.com.

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]